Soliris (eculizumab) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 85 Diseases   26 Trials   26 Trials   4609 News 


«12...678910111213141516...5758»
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Real-World Treatment Pathways Among Adult Patients with Myasthenia Gravis () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_962;    
    Differences in this proportion across data sources suggest the possibility of primary nonadherence: patients receiving but not filling prescriptions. A substantial proportion of patients trialing many therapies suggests high remaining unmet need.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review:  Meningococcemia in a vaccinated child receiving eculizumab and review of the literature. (Pubmed Central) -  Mar 8, 2023   
    In this case report and review, we discussed similar pediatric case reports in terms of meningococcal serotypes, vaccination history, antibiotic prophylaxis and prognosis of patients who experienced meningococcemia under eculizumab treatment. This case report highlights the importance of a high index of suspicion for invasive meningococcal disease.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Atrophic Papulosis. (Pubmed Central) -  Mar 6, 2023   
    Treatment is empirical with the use of antiplatelet therapy, anticoagulants, steroids, intravenous immunoglobulins, and immunosuppressive agents. Recent evidence shows that eculizumab, a complement inhibitor, is the most effective therapy in malignant AP with gastrointestinal involvement of the disease and should be combined with treprostinil to prevent relapse.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder. (Pubmed Central) -  Mar 6, 2023   
    Recent evidence shows that eculizumab, a complement inhibitor, is the most effective therapy in malignant AP with gastrointestinal involvement of the disease and should be combined with treprostinil to prevent relapse. No abstract available
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Costs and Utilization of New-to-Market Neurologic Medications. (Pubmed Central) -  Mar 2, 2023   
    Given the high costs and similar efficacy for most of the new medications, limited utilization may be appropriate. However, for new medications with greater efficacy, future studies are needed to determine whether high costs are a barrier to utilization.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Enrollment change, Trial completion date, Trial suspension, Trial primary completion date:  The Use of Eculizumab in HELLP Syndrome (clinicaltrials.gov) -  Feb 27, 2023   
    P1,  N=3, Suspended, 
    Recovery of visual acuity may lag behind resolution of macular edema in these patients. N=15 --> 3 | Trial completion date: Jan 2023 --> Jun 2023 | Recruiting --> Suspended | Trial primary completion date: Dec 2022 --> May 2023
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca, Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
    Review, Journal:  Medical emergencies in pediatric blood & marrow transplant and cellular therapies. (Pubmed Central) -  Feb 24, 2023   
    Myelosuppression secondary to the chemotherapy increases risk for engraftment syndrome as well as coagulopathies, thus increasing the risk for clotting and bleeding in the pediatric population. The purpose of this article is to review recent literature in these complications seen with pediatric hematopoietic cell transplant (HCT) and cellular therapies and provide a comprehensive summary of the major emergencies seen with HCT.
  • ||||||||||  Elizaria (eculizumab biosimilar) / Generium
    Enrollment closed, Trial completion date:  NAP: Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria (clinicaltrials.gov) -  Feb 23, 2023   
    P=N/A,  N=44, Active, not recruiting, 
    The purpose of this article is to review recent literature in these complications seen with pediatric hematopoietic cell transplant (HCT) and cellular therapies and provide a comprehensive summary of the major emergencies seen with HCT. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Apr 2023
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  The case for complement component 5 as a target in neurodegenerative disease. (Pubmed Central) -  Feb 14, 2023   
    C5 also has huge therapeutic potential in this arena, with its druggability clearly demonstrated by the success of C5-inhibitor eculizumab...Key hurdles that need to be overcome for this to be achieved are understanding how C5a and C5b should be targeted to bring therapeutic benefit and demonstrating the ability to target C5 without creating vulnerability to infection in patients. This requires greater biological elucidation of its precise role in disease pathogenesis, supported by better chemical/biological tools.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  Ocular Myasthenia Gravis: A Current Overview. (Pubmed Central) -  Feb 14, 2023   
    Reliable and consistent biomarkers are required to assess disease severity and response to therapy to optimize the management of OMG. The purpose of this review is to summarize the current trends and the latest developments in diagnosing and treating OMG.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca, Ultomiris IV (ravulizumab IV) / AstraZeneca
    Journal:  Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (Pubmed Central) -  Feb 12, 2023   
    P3
    The included Japanese patients with PNH preferred ravulizumab because of its reduced infusion frequency, which increases activity planning ability, treatment convenience, and overall quality of life, as compared with eculizumab. These data provide useful insight into patient perspectives and may aid decision-making for PNH treatment.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    PEDIATRIC PATIENTS WITH VERY SEVERE APLASTIC ANEMIA AND HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY CAN BE SUCCESSFULLY TREATED WITH ECULIZUMAB (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1771;    
    To our knowledge, this is the largest cohort of hrTA-TMA patients with very SAA treated with eculizumab. Despite the high-risk profile, the response rate and overall survival were high.To conclude, special attention should be taken to very SAA who received pre-transplant immunosuppression, as they are at particular risk of developing hrTA-TMA: early detection strategies, aggressive treatment of concomitant complications, intensifying the initial induction dose and eculizumab pharmacokinetic monitoring could be of utmost importance to achieve the best outcomes.
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    CENTRAL NERVOUS SYSTEM INVOLVEMENT IN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PEDIATRIC CASE (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1707;    
    On day +113 he met the Jodele 2015 criteria for atypical thrombotic microangiopathy, CsA was discontinued and he received eculizumab with improvement.In this context of profound immunosuppression, on day +176 he suffered tonic-clonic crisis...He started treatment with dexamethasone and antimicrobial coverage until the infectious cause was ruled out... - PTLDs with CNS involvement is an infrequent complication with unfavorable prognosis that requiries an agile diagnosis and treatment with Rituximab and urgent chemotherapy as well as withdrawal of immunosuppression, if feasible.- Active surveillance should be performed in patients with known risk factors and profound immunosuppression, as in our case.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    USE OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH HIGH-RISK TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY  (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1661;    
    Special attention should be taken to patients with extrarenal involvement and with those who require intensive care support. Strategies of early detection with close monitoring of proteinuria and sC5b9, aggressive treatment of concomitant complications (viral reactivations and GvHD), intensifying the initial induction dose and eculizumab pharmacokinetic monitoring could be the future goals to achieve better results in this severe and still frequently fatal complication.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, Soliris (eculizumab) / AstraZeneca
    OVERLAP OF TA-TMA VS ACUTE GVHD IN THE GASTROINTESTINAL TRACT: TWO CHALLENGING CASE REPORTS (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1546;    
    These two cases outlined that TA-TMA diagnosis is extremely difficult in some settings such as GI involvement, when the clinical features are the same of GvHD and laboratory criteria are not satisfied. When TA-TMA is suspected, calcineurin inhibitors should be promptly suspended.
  • ||||||||||  HIGH-RISK TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA), SINGLE CENTRE EXPERIENCE (ePoster Area) -  Feb 11, 2023 - Abstract #EBMT2023EBMT_1510;    
    Exclusion criteria include prior treatment with eculizumab, ravulizumab, or defibrotide within 3 months prior to screening, having Shiga toxin-producing E. coli hemolytic uremic syndrome (STEC-HUS), or ADAMTS13 activity <10%.Patients will receive narsoplimab 4 mg/kg via intravenous (IV) infusion twice weekly during the 8-week treatment period (Days 1 Four patients were diagnosed with GVHD before the onset of TA-TMA; in these patients the first intervention was to interrupt treatment with calcineurin inhibitors and administer mycophenolate mofetil and methylprednisolone 1-2 mg/kg/day...At a median follow up of 362 days from HSCT, 3/5 (60%) patients are alive; patient 1 died of leukemia relapse, patient 3 died of sepsis following multiple lines of treatment with concurrent remission of TA-TMA.Pt n
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Efficacy of Eculizumab in refractory NMOSD (Pacific Ballroom) -  Feb 7, 2023 - Abstract #ACTRIMSForum2023ACTRIMS_Forum_208;    
    Abstract is embargoed at this time. Abstract is embargoed at this time.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Dual inhibition of complement C5 and CD14 attenuates inflammation in a cord blood model. (Pubmed Central) -  Feb 2, 2023   
    Adding CD14 and complement C5 inhibitors up to 30 min after incubation of E. coli or Group B streptococci in a human umbilical cord blood model significantly reduced complement activation and cytokine release. Dual inhibition of C5 and CD14 is a potential future therapy to modulate systemic inflammation in severe cases of neonatal sepsis.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Journal:  Chemotherapy-Associated Thrombotic Microangiopathy. (Pubmed Central) -  Jan 28, 2023   
    However, the data is limited and unlike in primary atypical hemolytic uremic syndrome, the role of complement in the pathogenesis of drug-induced TMA is unclear. Larger multicenter studies and unified definitions are needed to elucidate the extent of the problem and potential treatment strategies.
  • ||||||||||  Review, Journal:  Rise of the planet of rare anemias: An update on emerging treatment strategies. (Pubmed Central) -  Jan 27, 2023   
    PNH treatment is moving from the intravenous anti-C5 eculizumab to its long-term analog ravulizumab, and to subcutaneous and oral proximal inhibitors (anti-C3 pegcetacoplan, factor D and factor B inhibitors danicopan and iptacopan)...Finally, the addition of eltrombopag significantly ameliorated AA outcomes, and data regarding the alternative agent romiplostim are emerging. The accelerated evolution of treatment strategies will need further effort to identify the best candidate for each treatment in the precision medicine era.